ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026
Clinical staging and profiling of affective disorders.
Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neuropsychiatric illness in the later years of life: summary and synthesis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical staging models are used to classify the stages of development of disorders across medicine. In this narrative review we explored whether staging in affective disorders may (i) improve the prediction of clinical outcomes, (ii) provide a more precise allocation of treatments to specific patients (iii) whether staging may serve as a framework to proactively integrate prevention and early intervention in the treatment of patients, and (iv) to direct research to studies of factors determining illness progression. Finally we examined (v) why staging may be especially salient in geriatric psychiatry and whether specific staging models are necessary for older patients. Our scope with regard to affective disorders was broad, including both unipolar and bipolar disorders. Although psychiatry has been late in resuming an interest in clinical staging, empirically tested models are available, which may be reliably used to stage the development of affective disorders. Clinical staging, in combination with data about comorbidity and clinical profilers may serve to improve treatment allocation. Progression from early at-risk stages to first episodes remains understudied, but there is sufficient evidence to conclude that prevention or postponement of early progression and the recurrence of affective disorders is effective. Given the change in risk factors, increase in comorbidity and worse prognosis of depression in later life, staging may be especially helpful in older patients. However, this does not mean that other staging models need to be developed, specifically for later life.
Identifiers
41580569What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.